No relationship between Taq1 A polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 96, Issue 3, 2000, Pages 422-424

  Mihara, Kazuo ^a   Suzuki, Akihito ^a   Kondo, Tsuyoshi ^a   Nagashima, Udai ^a   Ono, Shingo ^a   Otani, Koichi ^b   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Bromperidol; Dopamine D2 receptor; Extrapyramidal adverse effects; Nemonapride; Taq1 A polymorphism

Indexed keywords

BROMPERIDOL; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMILACE; EMONAPRIDE; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SCHIZOPHRENIA;

ACUTE DISEASE; ALLELES; ANTIPSYCHOTIC AGENTS; BENZAMIDES; DOPAMINE ANTAGONISTS; EXTRAPYRAMIDAL TRACTS; FEMALE; HALOPERIDOL; HUMANS; MALE; PILOT PROJECTS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 0034640689     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/1096-8628(20000612)96:3<422::AID-AJMG35>3.0.CO;2-5     Document Type: Article

References (15)

1. Casey DE. 1991. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109-120.
2. Chen CH, Wei FC, Koong FJ, Hsiao KJ. 1997. Association of Taq1 A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 41:827-829.
3. Grandy DK, Zhang Y, Civelli O. 1993. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 2:2197.
4. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. 1989. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J Chromatogr 495:227-234.
5. Jönsson E, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, Sedvall G. 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296.
6. Kondo T, Otani K, Ishida M, Tanaka O, Kaneko D, Fukushima Y. 1994. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 16:120-124.
7. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76(Suppl. 334):11-100.
8. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Ohtani K, Kaneko S. 1998. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J Chromatogr B 714:293-298.
9. Noble EP. 1998. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 16:33-45.
10. Otani K, Kondo T, Yasui N, Suzuki A, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K, Hayashi K. 1997. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum Psychopharmacol 12:591-594.
11. Schotte A, Bonaventure P, Janssen PFM, Leysen JE. 1995. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J Pharmacol 69:399-412.
12. Seeman P. 1995. Dopamine receptors. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 295-302.
13. 3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur J Pharmacol 173:177-182.
14. Thompson J, Thomas N, Singleton A, Piggott M, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA. 1997. D2 dopamine receptor (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7: 479-484.
15. Yasui N, Kondo T, Otani K, Ishida M, Mihara K, Suzuki A, Kaneko S, Inoue Y. 1998. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol Toxicol 82:153-156.